Therapy-related acute leukemia associated with involvement of 11q23 after high grade non-Hodgkin lymphoma.
Therapy-related acute myeloid leukemias with balanced translocations affecting the 11q23 chromosome region are one of the most serious complications of treatments with topoisomerase II inhibitor drugs as epipodophillotoxins and anthracyclines. 1,2-5 These cases are usually associated with short interval time from previous chemotherapies, absence of myeloid dysplastic phase, hyperleukocytosis and young age. We and others have recently identified and cloned the ALL1 gene at 11q23 band (also named MLL, HRX. Hrxt) which is consistently altered in t-AML following therapies with topo II targeting drugs. However, there are few reports of cases of t-AML, clinically and biologically similar to the subtype of leukemias secondary to exposure to topo II inhibitors drugs but without the involvement of the ALL1 gene. These observations suggest that genes other than ALL1 which are etiopathogenetically relevant for hematological neoplasias are located in this cytogenetic region.
Martinelli
G
G
Testoni
N
N
Zinzani
P L
PL
Biondi
A
A
Cimino
G
G
Tura
S
S
D000208:Acute Disease; D000328:Adult; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics*; D064420:Drug-Related Side Effects and Adverse Reactions; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000235:genetics*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications*; D008297:Male; D059005:Topoisomerase II Inhibitors; D014178:Translocation, Genetic / Q000235:genetics
D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors